J Korean Neuropsychiatr Assoc.  2022 Aug;61(3):224-236. 10.4306/jknpa.2022.61.3.224.

Korean Medication Algorithm Project for Bipolar Disorder 2022: Children and Adolescents

• Yang CM
• Bahk WM
• Woo YS
• Jeong JH
• Seo JS
• Choo IH
• Kim W
• Lee JG
• Jung MH
• Jon DI
• Park SY
• Sohn I
• Kim MD
• Yoon BH
• Shim SH

• KMID: 2532704
• DOI: http://doi.org/10.4306/jknpa.2022.61.3.224

Abstract

Objectives
The objective of this study was to revise the Korean Medication Algorithm Project for Bipolar Disorder (KMAP-BP) 2022: children and adolescents.
Methods
We performed a survey, using a questionnaire comprising 23 questions according to various situations facing children and adolescents with bipolar disorders. A total of 40 of the 60 experts in child and adolescent psychiatry responded to the survey.
Results
The first-line pharmacotherapeutic strategies for manic and depressive episodes in children with bipolar disorders were a combination of mood stabilizer (MS) and atypical antipsychotics (AAP). The first-line medications selected for these children were aripiprazole (treatment of choice, TOC) and risperidone. The first-line pharmacotherapeutic strategies for manic episodes in adolescents were a combination of MS and an AAP (TOC), monotherapy with MS, and monotherapy with an AAP. Lithium, valproate, aripiprazole, risperidone, and quetiapine were selected as first-line medications for these adolescents. First-line pharmacotherapeutic strategies for depressive episodes in adolescents were a combination of MS and an AAP, monotherapy with MS, and monotherapy with an AAP. The first-line pharmacotherapeutic strategies for the depressive episodes in adolescents at high risk for bipolar disorder were a combination of MS and AAP and monotherapy with an AAP. Lithium, valproate, aripiprazole (TOC), quetiapine, and risperidone were selected as first-line medications for the treatment of depressive episodes in adolescents with bipolar disorder.
Conclusion
It is expected that the present KMAP-BP 2022: children and adolescents will give the direction and be usefully applied by clinicians to treat children and adolescents with bipolar disorders.

Keyword

Bipolar disorder; Children and adolescents; Pharmacotherapy; KMAP-BP 2022